Depo-Provera Meningioma Brain Tumor

What Is a Depo-Provera Meningioma?

A meningioma is a tumor arising from the meninges — the protective membranes surrounding the brain and spinal cord. Depo-Provera's active ingredient (medroxyprogesterone acetate) is a synthetic progestin that binds to progesterone receptors on meningioma cells, stimulating tumor growth. Meningiomas express progesterone receptors at rates of 60–80%, making them uniquely vulnerable to synthetic progestin stimulation.

Meningioma Risk by Duration of Use

The risk increases with cumulative Depo-Provera exposure: ≤1 year use: 23% increased risk; 1–3 years: 150% increased risk (OR 2.50); >3 years: up to 460% increased risk (OR 5.6 in the French BMJ study). This dose-response relationship is critical evidence in the litigation because it demonstrates a causal mechanism rather than a coincidental association.

Meningioma Types and Grades

WHO Grade I meningiomas (80%) are slow-growing and typically benign but can still cause serious symptoms requiring surgical intervention. WHO Grade II (atypical, 15–20%) are more aggressive with higher recurrence rates. WHO Grade III (malignant, 1–3%) are cancerous and carry the most severe prognosis. All grades are included in the litigation.

Treatment Options

Treatment depends on tumor size, location, and grade. Options include: craniotomy (surgical removal), stereotactic radiosurgery (Gamma Knife), radiation therapy, and active surveillance with serial MRI imaging. Many patients require ongoing neurological monitoring even after successful surgery due to recurrence risk.